Loading...
Market
Will Neffy be prescribed more than 100,000 times in the U.S. by June 30, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Prescription data from healthcare analytics firms or government health agencies
Story
FDA Approves Neffy, First Needle-Free Epinephrine Treatment for Anaphylaxis
Aug 9, 2024, 04:52 PM
The U.S. Food and Drug Administration (FDA) has approved a new epinephrine nasal spray, neffy, developed by ARS Pharmaceuticals, as the first needle-free treatment for severe allergic reactions, including anaphylaxis. This approval, announced on Friday, marks a significant advancement in the treatment of allergic emergencies, offering an alternative to traditional epinephrine auto-injectors like the EpiPen. The nasal spray is approved for use in adults and pediatric patients who weigh at least 66 pounds. The FDA's decision is seen as a major step in improving accessibility and ease of use for individuals at risk of life-threatening allergic reactions.
View original story
Similar markets
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,001 to 10,000 • 25%
More than 10,000 • 25%
Less than 500 • 25%
500-1000 • 25%
1001-2000 • 25%
More than 2000 • 25%
Less than 1 million • 25%
1 million to 2 million • 25%
2 million to 3 million • 25%
More than 3 million • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
Less than 100,000 • 25%
100,000 to 200,000 • 25%
200,000 to 300,000 • 25%
More than 300,000 • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than 1 million units • 25%
1 to 2 million units • 25%
2 to 3 million units • 25%
More than 3 million units • 25%